FDA will distinguish most innovator biologics and biosimilars with a suffix added to their nonproprietary name, but the long-awaited plan leaves some important questions unanswered.
The agency intends to add the four-letter code to newly approved biologics as well as already-approved products.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?